Literature DB >> 1988005

Cholesterol esterification rates in very low density lipoprotein- and low density lipoprotein-depleted plasma. Relation to high density lipoprotein subspecies, sex, hyperlipidemia, and coronary artery disease.

M Dobiasova1, J Stribrna, D L Sparks, P H Pritchard, J J Frohlich.   

Abstract

The fractional rate of cholesterol esterification in very low density lipoprotein- and low density lipoprotein-depleted plasma (FERHDL) was studied in normolipidemic subjects and in individuals with hyperlipidemia and proven coronary artery disease (CAD). The FERHDL was significantly higher than the FER in whole plasma and was significantly higher in normal men than in normal women. In addition, men and women with primary hyperlipidemia had significantly higher FERHDL values relative to their sex-matched controls. The most significant increases in FERHDL values, however, were observed in individuals with CAD. In all patient groups, FERHDL was positively correlated with plasma triglyceride concentration. In addition, FERHDL was negatively related to plasma high density lipoprotein (HDL) cholesterol concentration in all groups except in men with CAD and in normolipidemic women. The gradient gel electrophoretic pattern of HDL from individuals with either low or high FERHDL values indicated an inverse relation between this activity and the relative amount of HDL2b particles. FERHDL likely reflects the metabolic properties of the heterogeneous population of HDL particles in the plasma and may be a function of the relative content of larger and smaller HDL particles. It appears to be a sensitive and reliable functional measure of the particle size distribution in the HDL pool and one of potential clinical value in the assessment of risk for CAD.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1988005     DOI: 10.1161/01.atv.11.1.64

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  7 in total

1.  The triglyceride:high-density lipoprotein-cholesterol ratio and steno-occlusive disease in the intracranial arteries.

Authors:  Kyusik Kang; Kwangsub Lee; Sung-Hoon Chung
Journal:  J Thromb Thrombolysis       Date:  2011-07       Impact factor: 2.300

2.  Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography.

Authors:  Milada Dobiásová; Jiri Frohlich; Michaela Sedová; Marian C Cheung; B Greg Brown
Journal:  J Lipid Res       Date:  2011-01-11       Impact factor: 5.922

3.  Association of lecithin-cholesterol acyltransferase activity measured as a serum cholesterol esterification rate and low-density lipoprotein heterogeneity with cardiovascular risk: a cross-sectional study.

Authors:  Shigemasa Tani; Atsuhiko Takahashi; Ken Nagao; Atsushi Hirayama
Journal:  Heart Vessels       Date:  2015-04-19       Impact factor: 2.037

4.  A unique genetic and biochemical presentation of fish-eye disease.

Authors:  J A Kuivenhoven; E J van Voorst tot Voorst; H Wiebusch; S M Marcovina; H Funke; G Assmann; P H Pritchard; J J Kastelein
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

5.  Two different allelic mutations in the lecithin-cholesterol acyltransferase gene associated with the fish eye syndrome. Lecithin-cholesterol acyltransferase (Thr123----Ile) and lecithin-cholesterol acyltransferase (Thr347----Met).

Authors:  H G Klein; P Lohse; P H Pritchard; D Bojanovski; H Schmidt; H B Brewer
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

6.  Markedly accelerated catabolism of apolipoprotein A-II (ApoA-II) and high density lipoproteins containing ApoA-II in classic lecithin: cholesterol acyltransferase deficiency and fish-eye disease.

Authors:  D J Rader; K Ikewaki; N Duverger; H Schmidt; H Pritchard; J Frohlich; M Clerc; M F Dumon; T Fairwell; L Zech
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

7.  Association of lecithin-cholesterol acyltransferase activity and low-density lipoprotein heterogeneity with atherosclerotic cardiovascular disease risk: a longitudinal pilot study.

Authors:  Katsuaki Yokoyama; Shigemasa Tani; Rei Matsuo; Naoya Matsumoto
Journal:  BMC Cardiovasc Disord       Date:  2018-12-05       Impact factor: 2.298

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.